Status:
COMPLETED
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
Rutgers University
Conditions:
Alzheimer Disease
Diabetes Mellitus, Type 2
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will provide a successful means for promoting circadian entrainment and treating metabolic disease and inflamma...
Detailed Description
Alzheimer's disease (AD) and type 2 diabetes (T2DM) pose linked, major threats to aging societies worldwide, but the relationship between these two diseases remains poorly understood. Hence, insulin r...
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate Alzheimer's disease or related dementia,
- sleep disturbance as determined by a score ≥ 5 on the PSQI
Exclusion
- insulin-dependent diabetes,
- urinary incontinence
- obstructing cataracts
- macular degeneration
- blindness
- severe sleep apnea or
- restless leg syndrome (RLS)
Key Trial Info
Start Date :
November 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT03777722
Start Date
November 19 2018
End Date
May 31 2025
Last Update
September 12 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Rutgers University
New Brunswick, New Jersey, United States, 08854
2
Icahn School of Medicine at Mount Sinai
Albany, New York, United States, 12204
3
Icahn School of Medicine
New York, New York, United States, 10029